OncoMatch/Clinical Trials/NCT05077280
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
Is NCT05077280 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Immunotherapy for uveal melanoma.
Treatment: Immunotherapy — This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: Opdualag or relatlimab (Opdualag, relatlimab)
Prior therapy with Opdualag or relatlimab
Cannot have received: liver embolization
Previous liver embolization
Cannot have received: radiation therapy
Previous liver radiation
Lab requirements
Blood counts
WBC >2000, ANC >1500, Hgb >8
Kidney function
Creatinine < 3 x ULN
Liver function
AST & ALT < 2.5 x ULN; Bilirubin < 2 x ULN; Albumin >2.9
WBC>2000, ANC>1500, Hgb >8. Creatinine < 3 x ULN. AST & ALT < 2.5 x ULN Bilirubin < 2 x ULN. Albumin >2.9
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- California Pacific Medical Center Research Institute · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify